BCR and diffuse large B-cell lymphoma: First, patients with DLBCL receiving BCR inhibitors are typically treated simultaneously with multiagent immunochemotherapy regimens, making it hard to establish which mutations provide resistance to which agent, or indeed if sensitivity to the BCR inhibitor ever existed in the first place.